Anesthetic management using remimazolam in a patient with atrial flutter: a case report.

Remimazolam is a new intravenously administered ultra-short-acting benzodiazepine used in anesthesia or sedation. Remimazolam offers several advantages over other short-acting sedatives, including an organ-independent metabolism and rapid and predictable onset and recovery. Furthermore, remimazolam shows less cardiovascular-inhibitory effects than other anesthetics. Atrial flutter is a form of cardiac arrhythmia that is associated with serious health-related outcomes and a substantial economic burden. Acute onset of atrial flutter can cause cardiac dysfunction, hypotension, and myocardial ischemia. Moreover, patients with atrial flutter are likely to have an increased risk of both atrial fibrillation and stroke. In this case report, a patient with a 1-year history of atrial flutter underwent general anesthesia for robot-assisted laparoscopic prostatectomy. Using continuous remimazolam infusion, anesthesia and surgery were successfully completed without sudden changes in the patient's blood pressure, heart rate, or electrocardiogram. This case report describes the first reported use of remimazolam to induce general anesthesia in a patient with atrial flutter. The findings suggest that remimazolam can reduce the hemodynamic risk during anesthesia in patients with arrhythmias such as atrial flutter, and is a suitable option for anesthesia in patients with arrhythmias.